- UshStat® video selected to showcase theme of “Life-changing Research” --
Oxford, UK – 9 May 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update from the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Seattle, Washington (USA) on 5-9 May 2013. The ARVO annual meeting is the largest gathering of eye and vision researchers in the world and this year’s theme is “Life-changing Research”.
Oxford BioMedica’s collaborators at Oregon Health & Science University’s Casey Eye Institute, Portland, Oregon submitted a video to ARVO which featured a patient who has been treated with UshStat®. UshStat® is a novel gene-based treatment for Usher syndrome type 1B, the most common form of deaf-blindness, and was designed and developed by Oxford BioMedica using the Company's proprietary LentiVector® platform technology.
The video was awarded second place in a contest to promote the ARVO 2013 theme and was showcased at the Sunday 5 May, 2013 Keynote Session: click here to watch the video.
Oxford BioMedica also presented two posters entitled “Glaucoma-GT, a novel gene therapy treatment for primary open-angle glaucoma” (abstract ID: 2741 - A0185) and “The LentiVector® Gene Therapy Platform for Ocular Disease: a clinical update” (abstract ID: 2744 - A0188).
John Dawson, Chief Executive Officer of Oxford BioMedica, said: “Our ocular gene therapy programmes continue to receive recognition from the ARVO community and we thank our collaborators at OHSU’s Casey Eye Institute for their support.”
- Ends -
For further information, please contact:
Casey Eye Institute:
Tel: +1 503 494 7986
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321